Management of relapsed/ refractory AL amyloidosis - PubMed
7 hours ago
- #relapsed refractory
- #AL amyloidosis
- #salvage therapy
- Frontline therapy for systemic AL amyloidosis now includes daratumumab combined with bortezomib, cyclophosphamide, and dexamethasone (D-VCD), improving hematologic and organ response rates.
- Many patients still relapse, and there is no standard salvage regimen or optimal timing after daratumumab failure.
- Salvage options include next-generation proteasome inhibitors, immunomodulatory drugs, autologous stem cell transplant, BCL-2 inhibitors, CAR-T therapy, and bispecific antibodies.